CARsgen Therapeutics Holdings (2171) Fundamentals 2026 — Revenue Analysis | SniperIQ

4.99 on the HKSE. This SniperIQ fundamentals page covers CARsgen Therapeutics Holdings's valuation, profitability (net margin -77.9%), revenue (¥126M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is CARsgen Therapeutics Holdings's market cap?

CARsgen Therapeutics Holdings (2171) has a market capitalization of approximately HK$8.5B, trading at HK

4.99 on the HKSE. Market cap moves with the live share price.

What is CARsgen Therapeutics Holdings's P/E ratio?

CARsgen Therapeutics Holdings's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is CARsgen Therapeutics Holdings?

CARsgen Therapeutics Holdings runs a net profit margin of -77.9%, a gross margin of 63.6%, and an operating margin of -82.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does CARsgen Therapeutics Holdings generate?

CARsgen Therapeutics Holdings reported revenue of ¥126M for fiscal year 2025, with net income of -¥98M and earnings per share (EPS) of -0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does CARsgen Therapeutics Holdings pay a dividend?

CARsgen Therapeutics Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is CARsgen Therapeutics Holdings financially healthy?

CARsgen Therapeutics Holdings carries a debt-to-equity ratio of 0.08x and a current ratio of 5.73x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is CARsgen Therapeutics Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CARsgen Therapeutics Holdings (2171) the key facts are: market cap HK$8.5B, revenue ¥126M, 52-week range 10.87-28.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.